Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki )

Pradier, Olivier; Rave-Fränk, Margret; Lehmann, J.; Lücke, Eva; Boghun, O.; Hess, Clemens F.; Schmidberger, Heinz

doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1142>3.0.co;2-u

Cited by 34 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings demonstrated that the combined use of docetaxel and radiation improved the tumor response, compared with docetaxel or radiation alone (17,18). Recent studies demonstrated the cell-killing effects of radiation and docetaxel on squamous cell carcinoma (SCC) cell lines in vitro, and also demonstrated the same effect on SCC cells in vivo (19)(20)(21)(22)(23)(24). Although these studies described a significant anti-tumor effect under the concurrent use of docetaxel with radiation, the docetaxel solution that was used in the experiment was itself sufficient to kill the SCC cells, and the synergistic aspects of docetaxel used in combination with radiation were not reported (19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 94%

“…Recent studies demonstrated the cell-killing effects of radiation and docetaxel on squamous cell carcinoma (SCC) cell lines in vitro, and also demonstrated the same effect on SCC cells in vivo (19)(20)(21)(22)(23)(24). Although these studies described a significant anti-tumor effect under the concurrent use of docetaxel with radiation, the docetaxel solution that was used in the experiment was itself sufficient to kill the SCC cells, and the synergistic aspects of docetaxel used in combination with radiation were not reported (19)(20)(21)(22). We performed CRTx using a very low concentration of etoposide that is not capable of killing the cancer cells by itself (i.e., a non-cytocidal concentration), and demonstrated a marked anti-tumor effect in SCC cells (25).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Tabuchi

Ozawa

Koyanagi

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Esophageal squamous cell carcinoma (ESCC)is more sensitive to radiation and chemotherapy than other cancers of the digestive system, and combined modality therapy may represent a promising treatment method. The radiation-sensitizing effect of docetaxel on ESCC cell lines was investigated. A colony formation assay was performed in which ESCC cell lines (TE2, TE3) and A431 were exposed to docetaxel (from 1.0x10 -11 to 10 -7 M) for 3 h to determine the concentration of docetaxel that was not able to kill individual cells (i.e., the non-cytocidal concentration). Individual cell lines were then exposed to the non-cytocidal concentration of docetaxel prior to, during, and after irradiation to determine whether the timing of docetaxel administration affected cell survival. In addition, flow-cytometry was performed, and the cell cycle was examined prior to and after docetaxel exposure to assess the mechanism of docetaxel as a radiation sensitizer. Docetaxel exhibited a concentration-dependent cytocidal effect, with a different IC 50 for each cell type. Almost no cytocidal effect was observed at the following docetaxel concentrations: A431, ≤1.0x10 -10 M; TE-2 and TE-3, ≤1.0x10 -9 M. Concurrent treatment with docetaxel and radiation tended to decrease cell survival in all the cell lines compared with docetaxel or radiation alone. Cell survival was lowest when the cells were treated using X-ray irradiation after docetaxel exposure (p<0.05). Flow cytometry revealed that in all three cell lines, docetaxel exposure increased the G2/M cell fraction with a higher increase in the cell line that exhibited the highest radiosensitivity. This study demonstrated that the administration of docetaxel at a non-cytocidal concentration prior to radiotherapy produced a synergistic cell-killing effect in SCC cell lines.

show abstract

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Tabuchi

Ozawa

Koyanagi

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The activity of docetaxel in SCCHN, coupled with the drug's in vitro radiosensitizing properties (Creane et al, 1999;Mason et al, 1999;Pradier et al, 2001), provide the basis for clinical trials with docetaxel as a component of concurrent or alternating chemoradiation in locally advanced SCCHN (Koukourakis et al, 1999;Hesse et al, 2000;Tishler et al, 2002). Docetaxel-based chemoradiation regimens have been shown to be feasible and active as induction and adjuvant therapy.…”

Section: Docetaxel-based Chemoradiation Regimens For Locally Advancedmentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

“…Docetaxel has been shown to be an effective radiosensitiser in vitro (Creane et al, 1999;Pradier et al, 2001) and to act synergistically in the presence of radiation in preclinical models (Scagliotti and Turrisi, 2003). The feasibility of concurrent treatment with single-agent docetaxel and radiotherapy for unresectable advanced NSCLC was established in a series of small phase I studies (Koukourakis et al, 1998;Mauer et al, 1998), and response rates of up to 80% have been reported in phase II trials in this setting (Kim and Khuri, 2002).…”

mentioning

confidence: 99%

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer

Scagliotti

Szczęsna²,

Ramlau³

et al. 2006

Br J Cancer

View full text Add to dashboard Cite

This trial aimed to assess the feasibility and tumour control of concurrent chemoradiotherapy or radiotherapy alone after docetaxelbased induction chemotherapy in locally advanced non-small-cell lung cancer (NSCLC). Patients with stage IIIA/IIIB NSCLC received two 21-day cycles of induction chemotherapy with docetaxel (85 mg m À2 , day 1) plus cisplatin (40 mg m À2 , days 1 and 2). Patients without disease progression on day 43 were randomised to radiotherapy (2 Gy for 5 days week À1 ; total 60 Gy) alone or with docetaxel 20 mg m À2 once weekly every 6 weeks. Of 108 patients who received induction chemotherapy, 104 were evaluable for response. After induction chemotherapy, the overall response rate (ORR) was 44%; 91 (88%) patients had no disease progression and 89 were subsequently randomised to local treatment. After randomised therapy, the ORR was 53% (chemoradiotherapy 58%; radiotherapy 48%). Median survival and time to progression were 14.9 and 7.8 months, respectively, for chemoradiotherapy and 14.0 and 7.5 months, respectively, for radiotherapy. The most common toxicities during induction chemotherapy and randomised therapy were grades 3 -4 neutropenia and grade 3 lymphocytopenia, respectively. Docetaxel -cisplatin induction therapy followed by concurrent docetaxel and thoracic radiotherapy is a feasible treatment option, showing good clinical activity and tolerability, for locally advanced NSCLC.

show abstract

Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki )

Cited by 34 publications

References 17 publications

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer

Contact Info

Product

Resources

About